Could ketamine ease severe BPD symptoms? new pilot study aims to find out

NCT ID NCT07099534

Not yet recruiting Symptom relief Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This pilot study will test whether two intravenous infusions of ketamine, given 24 hours apart, can quickly reduce symptoms in 38 adults with severe borderline personality disorder (BPD). Participants also receive standard psychiatric care. The main goal is to see if symptoms improve by day 9, with follow-ups up to 3 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ketamine
What this could lead to: If it works, this could point toward a rapid-acting treatment option for severe BPD symptoms.
What could go wrong: This is a very small pilot study (38 people) with no placebo group, so results may not be reliable or generalizable. Ketamine can cause side effects like dissociation and nausea.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BORDERLINE PERSONALITY DISORDER (BPD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

borderline personality disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BORDERLINE PERSONALITY DISORDER (BPD) INFUSION OF KETAMINE IN SEVERE BORDERLINE PERSONALITY DISORDER

Contacts and locations

Locations

Toulouse Purpan University Hospital, Head of Psychiatry Clinic in the UF3 department

Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.